Halomine Inc. — Department of Defense SBIR Phase I: A19-166

Description

Combating the epidemic of infection, particularly given the rise of drug resistant pathogens, is a US Army priority. Disease caused by these organisms has been associated with increased healthcare costs, extended hospitalizations, and higher mortality rates. Statistics published by military medical facilities indicate that among combat casualties, complications due to infection are a leading cause of death beyond the first few days of injury. HaloCare™ advanced wound treatment is the next-generation in wound treatment combining potent advanced biofilm-fighting technology into hemostatic wound dressings. HaloCare™ is the first advancement in wound care in decades and has been shown to be a more effective, more biocompatible, and more cost effective solution.